FarmaForce sets unprecedented standard of excellence with fourth consecutive PRIME Awards ‘Sales Team of the Year’ win
FarmaForce has set a new standard for sales excellence after being recognised as Sales Team of the Year for the fourth consecutive year at the 15th annual PRIME Awards. The FarmaForce Nephrology Specialist Team, an Otsuka Australia and FarmaForce strategic partnership, won the 2019 Sales Team of the Year award for exceptional sales, excellence in […]
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today announced it has added a novel anticancer drug platform to its portfolio that has the ability to develop a range of cancer therapeutics. TEX Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable […]
Morningstar Quantitative Research Reports
Morningstar have recently released quantitative research reports on two iQGG ASX-listed companies: iQ3 Corp (ASX:IQ3) FarmaForce (ASX:FFC)
The iQ Group Global named as one of Australia’s Top 5 Most Innovative Health Companies
The iQ Group Global is honoured to be recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine in its relentless pursuit to create the medicines of tomorrow. The iQ Group Global ranked #5 on the Health Industries list, from more than 800 nominated […]
The iQ Group Global supports excellence in diabetes research
The iQ Group Global continued its commitment to unearthing cutting edge research in biosciences by supporting the Diabetes Australia Research awards last month. The awards, presented at NSW Parliament House on July 19, honour the people and institutions behind the research contributing to the prevention, management and cure for all types of diabetes. Diabetes Australia […]
iQGG Recognised as Top 10 Diabetes Care Solutions Provider
The iQ Group Global has been recognised by Med Tech Outlook magazine as one of the Top 10 Diabetes Care Solutions Providers in 2019. The Saliva Glucose Biosensor is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva, not blood. With this world-first technology, our global mission is to […]
Federal Budget 2018: $1.3b plan to make Australia a medical technology leader
Last night’s 2018 Federal budget saw a raft of funding and exciting initiatives aimed at further supporting Australia’s position as a global medical technology leader. Here’s how: Supporting Medical Research A 21st Century Medical Industry Growth Plan will deliver $1.3 billion to support Australia as a global health industry leader in medical technology, biotechnology and pharmaceuticals […]
Farmaforce quarterly cash flow report shows continued sales excellence
FarmaForce Limited (ASX:FFC) has delivered more evidence of its continued growth as Australia’s premier healthcare contract sales organisation (CSO) with its latest ASX announcement, showing a 100% increase in sales in Q3 FY19 compared to Q3 FY18. With a 57% compound annual growth rate (CAGR) over the last four years, FarmaForce is significantly outperforming Australia’s […]
Biotech vs The Budget 2019-20 video
Last week, Treasurer Josh Frydenberg announced the Morrison government’s Budget for 2019-20, should they win the federal election in May. In a newly released video, The iQ Group Global’s Senior Economist Laurence Parker-Brown explains the crucial changes needed to activate a thriving biotech industry in Australia – and why the industry cannot rely on government […]
Saliva Glucose Biosensor in Medgadget
The Saliva Glucose Biosensor and The iQ Group Global are in the headlines again, this time featuring on the homepage of popular medical technologies news site Medgadget. Read the article here.